ENTERO
Entero Healthcare Solutions Limited
Each stock's 10,000-path forecast, rendered as light.
Entero Healthcare Solutions Limited (ENTERO) Stock Analysis & Case Study
Is ENTERO a good buy? The data-driven verdict.
Entero Healthcare Solutions Limited (ENTERO) trades at ₹1,243,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Entero Healthcare Solutions Limited (ENTERO) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 41.9× earnings, ROE of 6.9%, a 53% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ENTERO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ENTERO ranks against the 2,373 companies in our screener
- ENTERO's market cap of 5,409 Cr ranks in the 67th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's book value of ₹388 ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's promoter holding of 52.4% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's 3-year profit (PAT) growth of 130.0% ranks in the top 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's 3-year revenue growth of 26.0% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's debt-to-equity ratio of 0.40x is lower than 42% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ENTERO overvalued? ENTERO P/E vs peers
ENTERO trades at 41.9× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ENTERO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.4y of ENTERO history (3%/yr drift, 39%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ENTERO 2027 | ₹785 | ₹1,285 | ₹2,106 | +3% |
| ENTERO 2028 | ₹656 | ₹1,330 | ₹2,694 | +7% |
| ENTERO 2029 | ₹575 | ₹1,375 | ₹3,287 | +11% |
| ENTERO 2030 | ₹529 | ₹1,423 | ₹3,824 | +14% |
| ENTERO 2031 | ₹482 | ₹1,472 | ₹4,492 | +18% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ENTERO goes up, or doubles?
The bull case for ENTERO
- Entero Healthcare Solutions Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,287.
The bear case & risks
- ENTERO's P/E of 41.9x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ENTERO's return on equity of 6.9% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹575.
ENTERO volatility & expected range, how bumpy is the ride?
Over the last 2.4 years ENTERO compounded at 3%/year with annualized volatility of 39%. That volatility implies a 1-year 80% range of ₹785-₹2,106, the honest backbone behind any single price target.
ENTERO price forecast, the full 60-month probability fan
ENTERO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ENTERO hits common targets within the simulated horizon?
Full multi-horizon detail on the ENTERO price target & forecast page.
ENTERO Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ENTERO scores 5/8, mixed financial health.
ENTERO MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy ENTERO with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| ZerodhaCHEAPEST | 32.73% | 3.1× |
| Groww | 32.88% | 3.0× |
| Dhan | 32.73% | 3.1× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 32.98% | 3.0× |
| Pocketful | 32.96% | 3.0× |
| Anand RathiCHEAPEST | 32.73% | 3.1× |
| Bajaj Broking | 34.00% | 2.9× |
| Share India | 32.85% | 3.0× |
Compare every broker on the ENTERO MTF page.
About Entero Healthcare Solutions Limited: sector, index & market-cap context
Entero Healthcare Solutions Limited (ENTERO) is a small-cap NSE-listed company, with a market capitalisation of ₹5,409 Cr. See more stocks on our screener.
How the ENTERO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Entero Healthcare Solutions Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ENTERO analysis, FAQs
Is Entero Healthcare Solutions Limited (ENTERO) a good buy?
On the numbers, Entero Healthcare Solutions Limited (ENTERO) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 41.9× earnings, ROE of 6.9%, a 53% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ENTERO overvalued or undervalued?
ENTERO trades at 41.9× earnings, expensive versus the ~22× long-run Nifty average.
What is the ENTERO share price target for 2031?
ENTERO's probability-weighted 2031 median target is ₹1,472, with an 80% range of ₹482-₹4,492 (10,000-path Monte-Carlo).
What is the probability ENTERO doubles in 5 years?
The modelled probability of ENTERO reaching ₹2,485 (2×) within 5 years is 27%.
What is the bull case for ENTERO?
Entero Healthcare Solutions Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in ENTERO?
ENTERO's P/E of 41.9x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ENTERO's return on equity of 6.9% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.